Now showing items 21-30 of 79
T and B subtypes of prolymphocytic leukemias (PLLs) are rare, highly aggressive lymphoid malignancies with characteristic morphologic, immunophenotypical, cytogenetic, and molecular features. Recent studies have highlighted ...
Short-term presurgical treatment for all?
(BIOMED CENTRAL LTD, 2007-01-01)
Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin’s lymphoma with leukemia
Background and Objectives. A female patient presented with splenomegaly and lymphocytosis with atypical lymphoid cell morphology, We identified t(2;7)(p12;q21) prompting studies of the translocation breakpoint and its ...
Case 33. Diagnostic difficulty in a patient with acute leukemia
(Taylor & Francis, 2007-01-01)
Comparative genomic hybridization and amplotyping by arbitrarily primed PCR in stage A B-CLL
Cytogenetic analysis is useful in the diagnosis and to assess prognosis of B-cell chronic lymphocytic leukemia (B-CLL). However, successful cytogenetics by standard techniques has been hindered by the low in vitro mitotic ...
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review
(NATURE PUBLISHING GROUP, 2004-03)
The analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and ...
New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders
Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative ...
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
De novo resistance to endocrine therapy is a near-universal feature of oestrogen receptor (ER)- negative breast cancer. Although many ER-positive breast cancers also show no response to tamoxifen or aromatase inhibitors ...
Isolated bone marrow involvement in diffuse large B cell lymphoma: A report of three cases with review of morphological, immunophenotypic and cytogenetic findings
(TAYLOR & FRANCIS LTD, 2004-04)
Diffuse large B cell lymphoma (DLBL) comprises a heterogenous entity characterized by the presence of large cells, exhibiting a mature B cell phenotype. The high proliferation rate and aggressive disease remain a therapeutic ...